A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.

Hykin Philip G.; Vasconcelas Joana; Prevost Toby; Sivaprasad Sobha; Hounsome Barry; Chakravarthy Usha; Harding Simon; Lotery Andrew; Yang Yit C.; Sen Piyali; Ramu Jayashree; Nicholson Luke; Peto Tunde

首页> 外文期刊>Investigative ophthalmology & visual science >A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.

【24h】

A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.

机译：一种多长期双掩盖随机控制的非劣级试验比较术治疗术治疗（Lucentis）术治疗（Lucentis）与AfliBelcept（Eylea）对黄斑静脉闭塞（eylvo）的临床和成本效果Vs Aflibercept（eylea）对黄斑水肿（Avastin），因为中央视网膜静脉闭塞[leavo]：基线患者社会学和眼睛特征。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Investigative ophthalmology & visual science》 |2018年第9期|共5页
作者
Hykin Philip G.; Vasconcelas Joana; Prevost Toby; Sivaprasad Sobha; Hounsome Barry; Chakravarthy Usha; Harding Simon; Lotery Andrew; Yang Yit C.; Sen Piyali; Ramu Jayashree; Nicholson Luke; Peto Tunde;
展开▼
作者单位

Moorfields Eye Hosp London England;

Imperial Coll London England;

Imperial Coll London England;

Moorfields Eye Hosp London England;

Kings Coll CTU London England;

Queens Univ Belfast Belfast Antrim North Ireland;

Univ Liverpool Liverpool Merseyside England;

Univ Southampton Southampton Hants England;

Royal Wolverhampton NHS Trust Wolverhampton W Midlands England;

Moorfields Eye Hosp London England;

Moorfields Eye Hosp London England;

Moorfields Eye Hosp London England;

Queens Univ Belfast Belfast Antrim North Ireland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献

1. A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics. [J] . Hykin Philip G., Vasconcelas Joana, Prevost Toby, Investigative ophthalmology & visual science . 2018,第9期

机译：一种多长期双掩盖随机控制的非劣级试验比较术治疗术治疗（Lucentis）术治疗（Lucentis）与AfliBelcept（Eylea）对黄斑静脉闭塞（eylvo）的临床和成本效果Vs Aflibercept（eylea）对黄斑水肿（Avastin），因为中央视网膜静脉闭塞[leavo]：基线患者社会学和眼睛特征。
2. CONCEPTUAL MODELLING FOR COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL THERAPY WITH RANIBIZUMAB, AFLIBERCEPT OR BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION [J] . Goodall M., Tosh J., Alshreef A., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：由于视网膜中央静脉闭塞，黄斑性乙状结肠炎用兰尼单抗，阿维贝舒或贝伐珠单抗对玻璃体腔内治疗的成本效益分析的概念模型
3. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion A Randomized Clinical Trial [J] . Hykin Philip, Prevost A. Toby, Vasconcelos Joana C., JAMA ophthalmology . 2019,第11期

机译：宫颈疗法与Ranibizumab的临床疗效与AfliBelcept对中央视网膜静脉闭塞的黄斑水肿vs Aflibercept Vs Aflibercept vs Aflibelcepab。随机临床试验
4. Comment on: ‘Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab [O] . D Călugăru, M Călugăru 2016

机译：评论：玻璃体腔注射阿柏西普可用于接受贝伐单抗或兰尼单抗治疗的患者继发于视网膜中央静脉阻塞继发的黄斑水肿
5. Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion [O] . Goodall M., Tosh J., Alshreef A.O., 2016

机译：Ranibizumab，aflibercept或Bevacizumab玻璃体内注射治疗因视网膜中央静脉阻塞引起的黄斑水肿的成本 - 效果分析的概念模型

著录项

相似文献

相关主题

期刊订阅